Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Year: 2018
Type: review
Abstract: infection during gestation, followed by treatment with spiramycin for acute maternal infections and with pyr-sulf for those with established fetal infection, has been shown to be effective at preventing vertical transmission and minimizing the severity of congenital toxoplasmosis (CT). Despite significant progress in treating human disease, there is a strong impetus to develop novel therapeutics for both the acute and latent forms of the infection. Here we present an overview of toxoplasmosis treatment in humans and in animal models. Additional research is needed to identify novel drugs by use of innovative high-throughput screening technologies and to improve experimental models to reflect human disease. Such advances will pave the way for lead candidates to be tested in thoroughly designed clinical trials in defined patient populations.
Source: Clinical Microbiology Reviews
DOI: 10.1128/cmr.00057-17
Authors: Ildiko Rita Dunay, Kiran Gajurel, Reshika Dhakal, Oliver Liesenfeld, Jose G. Montoya
Language: English
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2889776706